Diligence memo · auto-generated · as of July 2, 2026
Progentos Therapeutics, Inc.
Progentos Therapeutics, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Progentos Therapeutics, Inc. operates in Pharma, based in WATERTOWN.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Progentos Therapeutics, Inc. has raised $69M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $69M on 2024-05-03.
Most recent recorded round closed around 2024-05-03.
Valuation (modeled)modeled
Provath models Progentos Therapeutics, Inc. at approximately $635M (range $223M–$987M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Series C Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.2 yr ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 87% of Pharma peers (310 compared).
Modeled value ranks above 88% of those peers.
Closest niche peers: Circle Pharma, Inc., Averna Therapeutics Inc., Soleno Therapeutics Inc, Intrinsic Therapeutics Inc, Digital Therapeutics, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.